Giving semaglutide to people undergoing minimally invasive endoscopic sleeve gastroplasty may bring weight loss closer to that induced by bariatric surgery, shows research.
Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.